Xocova (Ensitrelvir): First Oral COVID-19 PEP Drug by Japan’s Shionogi

Key Takeaways

• Xocova reduces symptomatic COVID-19 risk by 67% in Phase III trial
• Approved for adults and adolescents 12+ within 72 hours post‑exposure
• Five‑day oral regimen adds first PEP option to US market
• Trial enrolled 2,387 participants, 99% had prior immunity
• Shionogi expands infectious‑disease portfolio beyond HIV and influenza

Pulse Analysis

Even as CDC data show COVID‑19 activity at historic lows, the virus still drives hundreds of thousands of hospitalizations each year. Seasonal spikes and emerging variants keep the threat alive, prompting public‑health officials to seek tools that can blunt transmission before illness takes hold. Post‑exposure prophylaxis fills that gap, offering a bridge between vaccination and treatment and potentially reducing the burden on emergency departments and inpatient wards.

Xocova’s mechanism as a main‑protease inhibitor mirrors that of existing antivirals, yet its timing is distinct. By blocking viral replication within 72 hours of exposure, the five‑day regimen prevents the virus from establishing a symptomatic foothold. The SCORPIO‑PEP trial, which enrolled 2,387 mostly immune‑experienced participants, demonstrated a 67% relative risk reduction, a result that rivals the efficacy of early‑treatment options while targeting a previously unserved window. Unlike Paxlovid, which is prescribed after symptom onset, Xocova is positioned as a pre‑emptive pill, expanding clinicians’ therapeutic arsenal.

For Shionogi, the approval marks a strategic pivot into COVID‑19 prevention, complementing its legacy in HIV, influenza and bacterial infections. The drug opens a new market segment, likely attracting insurers and employers seeking to limit outbreak costs in schools, workplaces, and congregate settings. As the industry watches, Xocova could spur additional PEP development, prompting competitors to explore similar oral candidates and reshaping the commercial landscape of pandemic preparedness.